Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia|May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian reportMartha L Louzada, Donna Reece, Christopher P Venner, et al.
Transplantation and Cellular Therapy|July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group DatabaseChristopher P Venner, Peter Duggan, Kevin Song, et al.
Frontiers in Oncology|March 7, 2022
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective AnalysisHira Mian, Christine Eisfeld, Christopher P Venner, et al.
Blood Cancer Journal|July 20, 2023
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Blood Cancer Journal|September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseJulie Côté, Richard LeBlanc, Hira Mian, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical DatabaseJulia Varghese, Christopher P Venner, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2025
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group DatabaseRayan Kaedbey, Christopher P Venner, Donna Reece, et al.
Cancer Medicine|November 5, 2024
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database StudyMégane Tanguay, Jean Roy, Jiandong Su, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Pageof 8